LUPUS ERYTHEMATOSUS, SYSTEMIC
Clinical trials for LUPUS ERYTHEMATOSUS, SYSTEMIC explained in plain language.
Never miss a new study
Get alerted when new LUPUS ERYTHEMATOSUS, SYSTEMIC trials appear
Sign up with your email to follow new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lupus pill shows promise in major trial
Disease control OngoingThis study tests a new drug, cenerimod, for adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo on top of their usual treatments for 12 months. The goal is to see if cenerimod can better control lupu…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 17, 2026 08:12 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 548 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for a year. The goal …
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 17, 2026 07:58 UTC
-
New lupus drug saphnelo tracked in Real-World study
Disease control OngoingThis study follows 1620 lupus patients who are not responding well to current treatments to see how safe and effective Saphnelo (anifrolumab) is over the long term. Researchers will monitor for side effects like infections and allergic reactions. The goal is to gather real-world …
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 07:58 UTC
-
New drug shows promise in taming lupus symptoms
Disease control OngoingThis study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe symptoms. About 451 adults with lupus will receive either cenerimod or a placebo for 12 months. The goal is to see if cenerimod reduces disease activity without causing se…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either high-dose, low-dose litifilimab, or a placebo as injections every 4 we…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 people who already completed a year-long study will take cenerimod for up to 3 more years, along with their usual lupus medications. Researchers will track side effects and se…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Lupus fatigue fight: coaching beats standard care?
Symptom relief OngoingThis study tests whether personalized coaching on physical activity and nutrition can reduce fatigue in people with lupus. 200 participants are split into two groups: one gets coaching on exercise and diet, the other gets standard lupus self-management education. The main goal is…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated May 17, 2026 08:03 UTC
-
New online program aims to keep arthritis patients on the job
Symptom relief OngoingThis study tests an online program designed to help people with inflammatory arthritis (like rheumatoid arthritis or lupus) keep their jobs. Participants get access to eLearning, an occupational therapist, and a vocational counselor. The goal is to see if the program improves wor…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: NA • Sponsor: University of British Columbia • Aim: Symptom relief
Last updated May 15, 2026 11:54 UTC
-
Pilates may ease lupus fatigue and boost quality of life
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether clinical pilates exercises can reduce fatigue, pain, and emotional distress in women with systemic lupus erythematosus (SLE). Researchers will measure changes in sleep, functional capacity, and quality of life in 30 women with low disease activity. The…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: NA • Sponsor: Emir İbrahim IŞIK • Aim: Symptom relief
Last updated May 11, 2026 20:53 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells (B cells) from people with autoimmune diseases like lupus, people with infections, and healthy volunteers. Researchers want to understand how these cells differ between groups. The goal is to learn more about the immune system, not to test a new t…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 17, 2026 08:12 UTC
-
Can a phone app help teens with lupus and depression stay on track?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how depression symptoms, like loss of interest, may make it harder for teens and young adults with lupus to keep up with their medical appointments. Researchers will test a mobile health app designed to improve both clinic engagement and depression. About 40 p…
Matched conditions: LUPUS ERYTHEMATOSUS, SYSTEMIC
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated May 01, 2026 15:59 UTC